Epizee 100 Injection

• Epizee 100 Injection is an Anticancer injection used to treat various cancers such as blood, breast, stomach, lung, ovaries, soft tissues, colon, and rectum.
• It is also used as an adjuvant treatment for breast cancer. Epizee 100 Injection contains epirubicin, an anthracycline antibiotic that directly kills cancer cells by targeting their DNA.​​
  

• Blood, Breast, Stomach, Lung, Ovaries, Soft Tissues, Colon, and Rectum Cancer

Epizee 100 Injection is an Anticancer injection. Its salt in reaction with the body leads to numerous side effects like any other medication. Symptoms may vary from mild to severe. If these side effects remain for longer period of time, consult your doctor immediately.

• Hair loss
• Mouth Sores
• Nausea
• Weakness
• Low Red, White and Platelets Blood Cell Count
• Fluid Retention
• Muscle Pain
• Nail Change
• Fever
• Rashes
• Diarrhea
• Hot Flashes
• Gastrointestinal Inflammation

• Febrile Nutropenia
• Allergic Reactions
• Heart Damage
• Severe Bone Suppression
• Secondary Cancers

• Epizee 100 Injection is administered intravenously, either alone or with other cancer treatment therapies, depending on the cancer's type and stage.
• Patients should not self-administer; it must be injected by a doctor or trained nurse. Consult a doctor for precise dosage and timing.​​
  

• Epizee 100 Injection contains epirubicin, an anthracycline antibiotic that directly kills cancer cells by targeting their DNA.
• Epirubicin inhibits topoisomerase II, an enzyme required for DNA replication, and intercalates into DNA strands to produce complexes that prevent the production of DNA and RNA.
• Cancer cells die because of, this damage, which stops cell division at every stage of the cell cycle.​​
  

• Conte, P. F., Gennari, A., Landucci, E., & Orlandini, C. (2000). Role of epirubicin in advanced breast cancer. Clinical breast cancer, 1, S46-S51.
• Plosker, G. L., & Faulds, D. (1993). Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs, 45(5), 788-856. https://pubmed.ncbi.nlm.nih.gov/7686469/
• Cersosimo, R. J., & Hong, W. K. (1986). Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. Journal of Clinical Oncology, 4(3), 425-439. https://pubmed.ncbi.nlm.nih.gov/3005521/
• Robert, J. (1994). Clinical pharmacokinetics of epirubicin. Clinical pharmacokinetics, 26(6), 428-438.